Amgen Inc $115.46

down -0.08


17/4/2014 08:10 PM  |  NASDAQ : AMGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get AMGN Trend Analysis - it has underperformed the S&P 500 by 15%

Partner Headlines

  1. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  2. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  3. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response ...

    Benzinga
  4. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  5. Cholesterol drug meets goal

    IBD
  6. Trial Results Lift Drug Sector

    IBD
  7. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  8. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  9. Gilead Adds To Biotech Woes

    IBD
  10. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  11. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  12. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  13. Biotech ETFs Come Back Down To Earth

    Benzinga
  14. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  15. BIOGEN IDEC

    IBD
  16. Have We Seen The Top Of The Market?

    Benzinga
  17. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  18. Amgen up on drug trial result

    IBD
  19. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  20. US Stock Futures Edge Lower Ahead Of Wholesale Trade Data

    Benzinga
  21. Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR ...

    Benzinga
  22. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  23. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  24. Insys Set To Report Q4 Earnings With Stock Surging

    IBD
  25. Why Stock Shakeouts Can Be Scary, Yet Constructive

    IBD
  26. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga
  27. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  28. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  29. France's Biosimilar Substitution May Lead to Erosion of Amgen

    Benzinga
  30. Why Mr. Cautious Is 82% Invested In Stocks

    YCharts
  31. Illumina, Alexion Lead 4 Big Caps Drawing Big Buyers

    IBD
  32. You Can No Longer Ignore Biotech

    GuruFocus
  33. Merck soars on cancer deal

    IBD
  34. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  35. Merck Misses Estimates in 4Q; Plans Increased Focus on Cancer

    FoxBusiness
  36. Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial ...

    Benzinga
  37. Pfizer, Amgen Earnings Beat

    IBD
  38. Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial ...

    Benzinga
  39. Earnings Scheduled For January 28, 2014

    Benzinga
  40. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  41. Amgen

    IBD
  42. Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of ...

    Benzinga
  43. Drugmaker Merck Tries To Jump-Start Slow Growth

    IBD
  44. Illumina, Jazz Among 5 Young Guns Hitting New Highs

    IBD
  45. Illumina Details Its Strategy; Stock Jumps Again

    IBD
  46. Market Wrap For January 16: Markets End Two Day Winning Streak

    Benzinga
  47. ILLUMINA

    IBD
  48. Drug Buyouts On The Rise -- But Buyers Changing

    IBD
  49. Amgen, Mass General, Broad Institute Collaborate on New Drugs for IBD

    Benzinga
  50. Biotech Stocks Back On Top, Led By Biogen, Alexion

    IBD
Trading Center